TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22299547

Group type: EXPERIMENTAL
Intervention: Ambu LMA
Number of subjects: 118

Group type: COMPARATOR
Intervention: Classic LMA
Number of subjects: 118
Study: 19903982

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg, 1 week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17037645

Group type: EXPERIMENTAL
Intervention: Individuals who reported prior out-of-body experiences (N=9)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Individuals who did not report prior out-of-body experiences (N=31)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Individuals who reported out-of-body experiences during the task (N=6)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Individuals who did not report out-of-body experiences during the task (N=34)
Number of subjects: 40
Study: 12916666

Group type: EXPERIMENTAL
Intervention: Flow cytometric tetraploidy and aneuploidy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dysplasia grade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17p (p53) LOH
Number of subjects: 0
Study: 11041004

Group type: EXPERIMENTAL
Intervention: Accountability for stock investment decision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counterfactual excuse-making
Number of subjects: 0
Study: 9680899

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 7770141

Group type: EXPERIMENTAL
Intervention: Non-wash system
Number of subjects: 9

Group type: COMPARATOR
Intervention: Wash system (Cell Saver Haemolite 2)
Number of subjects: 9
Study: 3364403

Group type: EXPERIMENTAL
Intervention: Ca citrate (750 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ca(H2PO4)2 (750 mg)
Number of subjects: 8
Study: 31021159

Group type: EXPERIMENTAL
Intervention: Dedicated feeding tube attachment device (FTAD)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Adhesive tape
Number of subjects: 104
Study: 27709360

Group type: EXPERIMENTAL
Intervention: Tocopherol-enriched Mediterranean meal (TEM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western high-fat meal (HFM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0
Study: 25359444

Group type: COMPARATOR
Intervention: Control (fifteen 40‐minute sessions of transcutaneous electrical nerve stimulation, microwave treatment, and standardized exercises)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: GDS‐I (eleven 50‐minute group GDS sessions plus four 50‐minute individualized GDS sessions)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: GDS‐G (eleven 50‐minute group GDS sessions)
Number of subjects: 461
Study: 23771800

Group type: EXPERIMENTAL
Intervention: PM00104 (Zalypsis) administered as a 1-h, weekly, intravenous infusion at a dose of 2 mg/m2 (days 1, 8, and 15; every 4 weeks)
Number of subjects: 19
Study: 21398178

Group type: EXPERIMENTAL
Intervention: Colonic stenting
Number of subjects: 98

Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 98
Study: 18804943

Group type: EXPERIMENTAL
Intervention: Aortobifemoral bypass (ABF)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Recanalization, percutaneous transluminal angioplasty, and stenting (R/PTAS)
Number of subjects: 169
Study: 16551142

Group type: EXPERIMENTAL
Intervention: Drug court with usual community services
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Drug court with multisystemic therapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Drug court with multisystemic therapy enhanced with contingency management
Number of subjects: 161

Group type: COMPARATOR
Intervention: Family court with usual community services
Number of subjects: 161
Study: 14607573

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) and zinc sulfate (66 mg)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 10892657

Group type: EXPERIMENTAL
Intervention: L-arginine (20-g oral dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8930680

Group type: EXPERIMENTAL
Intervention: Test mouthrinse containing sodium benzoate and alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test mouthrinse
Number of subjects: 20
Study: 8018144

Group type: EXPERIMENTAL
Intervention: Dapsone (100 mg twice weekly)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (100 mg every 2 weeks)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 278
Study: 3915459

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Domperidone maleate (20 mg t.i.d.)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ranitidine + Domperidone maleate
Number of subjects: 45
Study: 29439618

Group type: EXPERIMENTAL
Intervention: Prolonged GnRH agonist therapy (3 consecutive IM injections of triptorelin 3.75 mg 28 days apart)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard long protocol
Number of subjects: 90
Study: 27159342

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24166711

Group type: EXPERIMENTAL
Intervention: Intervention group (n=8 departments)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (n=7 departments)
Number of subjects: 293
Study: 23544775

Group type: EXPERIMENTAL
Intervention: Treatment for depression (specifics not provided, but benzodiazepines were used in 18% of patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study: 19660890

Group type: EXPERIMENTAL
Intervention: Computer-generated tailored letters
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Physician-delivered brief advice
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 1499
Study: 17655565

Group type: EXPERIMENTAL
Intervention: Yoga therapy (YT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Physical exercise therapy (PT)
Number of subjects: 61
Study: 16101703

Group type: EXPERIMENTAL
Intervention: Ultrasound prelocation (UL) using a TEE intraoperative probe
Number of subjects: 62

Group type: COMPARATOR
Intervention: Anatomical landmark method (AL)
Number of subjects: 62
Study: 12098160

Group type: EXPERIMENTAL
Intervention: Electromyographic activity of the VMO and vastus lateralis during rise task and rock task
Number of subjects: 74
Study: 10070170

Group type: EXPERIMENTAL
Intervention: enalapril (20 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: irbesartan (100 mg/day)
Number of subjects: 20
Study: 7717738

Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1646106

Group type: EXPERIMENTAL
Intervention: Ammonium chloride (NH4Cl) ingestion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion
Number of subjects: 18
Study: 298341

Group type: EXPERIMENTAL
Intervention: Beta-endorphin
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 1
Study: 31517505

Group type: EXPERIMENTAL
Intervention: Microcirculatory perfusion parameters (proportion of perfused capillaries)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Microcirculatory perfusion parameters (perfused capillary density)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Macrocirculatory perfusion parameters (systolic blood pressure)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Microcirculatory perfusion parameters (proportion of perfused capillaries) in normotensive patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Microcirculatory perfusion parameters (perfused capillary density) in normotensive patients
Number of subjects: 66
Study: 30570287

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 113
Study: 27183154

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.08 mg/kg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 161
Study: 25622599

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 228

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 228
Study: 23694718

Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel arm
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: KELIM (CA-125 elimination rate)
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: KPROD (CA-125 tumor production rate)
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: K (tumor growth rate)
Number of subjects: 895
Study: 21966787

Group type: EXPERIMENTAL
Intervention: Vaginal tablets (ketoconazole 800 mg + clindamycin 100 mg)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Vaginal capsules (ketoconazole 800 mg + clindamycin 100 mg)
Number of subjects: 169
Study: 19933717

Group type: EXPERIMENTAL
Intervention: Maraviroc with zidovudine/lamivudine
Number of subjects: 759

Group type: COMPARATOR
Intervention: Efavirenz with zidovudine/lamivudine
Number of subjects: 759
Study: 16401777

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 228
Study: 15528908

Group type: EXPERIMENTAL
Intervention: Essential oil (EO) mouthrinse
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse plus 100 mg/kg fluoride
Number of subjects: 24

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 24
Study: 11753327

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (toggle recoil)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 105
Study: 9286238

Group type: EXPERIMENTAL
Intervention: Apheresis and reinfusion of concentrated ascites (ARCA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Total paracentesis plus intravenous albumin (PARA)
Number of subjects: 24
Study: 8395725

Group type: EXPERIMENTAL
Intervention: Fraxiparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 0
Study: 3013571

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin with doxycycline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 20
Study: 31563820

Group type: EXPERIMENTAL
Intervention: ID-migraine questionnaire (PIN)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Visual aura rating scale (VARS)
Number of subjects: 240
Study: 29029571

Group type: EXPERIMENTAL
Intervention: Implementation intentions (II) training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Verbal rehearsal (VR) training
Number of subjects: 52
Study: 26461252

Group type: EXPERIMENTAL
Intervention: Expressive writing about a distressing experience for 15 minutes on 3 consecutive days (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expressive writing about a distressing experience for 15 minutes on 3 consecutive days (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison groups (non-emotional topic writing or thinking)
Number of subjects: 0
Study: 24190979

Group type: EXPERIMENTAL
Intervention: Ra-223 plus best standard of care (BSoC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus best standard of care (BSoC)
Number of subjects: 0
Study: 22649140

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomized (AR) design
Number of subjects: 140

Group type: COMPARATOR
Intervention: Multiarm balanced randomized (BR) design
Number of subjects: 140
Study: 20189472

Group type: EXPERIMENTAL
Intervention: Metoclopramide hydrochloride tablets
Number of subjects: 0
Study: 18022695

Group type: EXPERIMENTAL
Intervention: Urinary N(2)O >= 27 microg/l
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Urinary N(2)O < 27 microg/l
Number of subjects: 61

Group type: COMPARATOR
Intervention: Unexposed nurses
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Workers with urinary N(2)O >= 27 microg/l
Number of subjects: 61
Study: 15974489

Group type: EXPERIMENTAL
Intervention: Electroacupuncture on Zusanli points with IV atropine premedication
Number of subjects: 15

Group type: COMPARATOR
Intervention: Electroacupuncture on Zusanli points without atropine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo stimulation on a non-acupoint
Number of subjects: 15
Study: 12324914

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BHD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 9
Study: 10628604

Group type: EXPERIMENTAL
Intervention: Continuous infusion of pancuronium (n = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intermittent bolus of pancuronium (n = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 7862660

Group type: EXPERIMENTAL
Intervention: Plasma rich in anti-HIV-1 antibody
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard seronegative plasma
Number of subjects: 86
Study: 2029920

Group type: EXPERIMENTAL
Intervention: Green light phototherapy (Sylvania F20T12/G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blue light phototherapy (Philips TL/20W/52)
Number of subjects: 0
Study: 6115104

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 27
Study: 31151436

Group type: EXPERIMENTAL
Intervention: Autologous HSCT (haematopoietic stem cell transplant)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 99
Study: 28415975

Group type: EXPERIMENTAL
Intervention: Hula intervention for 6 months
Number of subjects: 250

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 250
Study: 26551773

Group type: EXPERIMENTAL
Intervention: 660-nm QS Nd:YAG laser
Number of subjects: 8

Group type: COMPARATOR
Intervention: 532-nm QS Nd:YAG laser
Number of subjects: 8
Study: 26158167

Group type: EXPERIMENTAL
Intervention: Laparoscopic microwave ablation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional opening group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Laparoscopic resection group
Number of subjects: 47
Study: 23117205

Group type: EXPERIMENTAL
Intervention: HUD‐VASH (intensive case management plus rent subsidy vouchers)
Number of subjects: 259

Group type: COMPARATOR
Intervention: ICM alone
Number of subjects: 259
Study: 19528841

Group type: EXPERIMENTAL
Intervention: sugar-free Red Bull energy drink (2 mg x kg(‐1) body mass caffeine or approximately 147 mg caffeine; 4 kcal/250 mL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: noncaffeinated, sugar-free placebo (lemon-lime flavored soft drink, tonic water, lime juice; 4 kcal/250 mL)
Number of subjects: 17
Study: 17304888

Group type: EXPERIMENTAL
Intervention: 2.5% hydrocortisone in moisturizing cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moisturizing cream alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No topical application
Number of subjects: 0
Study: 15802775

Group type: EXPERIMENTAL
Intervention: Various agents for treatment and prevention of osteoporosis, specific agents not mentioned, duration not specified.
Number of subjects: 0
Study: 12231498

Group type: EXPERIMENTAL
Intervention: MAS‐1 (4 mm of interincisal opening)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MAS‐2 (14 mm of interincisal opening)
Number of subjects: 23
Study: 10233200

Group type: EXPERIMENTAL
Intervention: 2.5 mg rizatriptan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg rizatriptan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg rizatriptan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15 mg rizatriptan
Number of subjects: 24

Group type: COMPARATOR
Intervention: 4 mg intravenous rizatriptan
Number of subjects: 24
Study: 7745314

Group type: EXPERIMENTAL
Intervention: Staged resection (group T)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Acute resection (group R)
Number of subjects: 121
Study: 2383801

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight followed by 2.5 mg/kg body weight 2 and 0.5 hours before exercise)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7054040

Group type: EXPERIMENTAL
Intervention: Intragastric feeding
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraduodenal feeding
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified sham feeding
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Essential amino acids infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oleic acid infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nutrients perfused into the distal small intestine
Number of subjects: 10
Study: 31222893

Group type: EXPERIMENTAL
Intervention: SCA 40%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study: 29108091

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose epinephrine (LDEPI) plus tranexamic acid (TXA)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Topical diluted epinephrine plus tranexamic acid (TXA)
Number of subjects: 195

Group type: COMPARATOR
Intervention: TXA alone (Control)
Number of subjects: 195
Study: 26361642

Group type: EXPERIMENTAL
Intervention: Music listening (n = 61)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (n = 60)
Number of subjects: 121
Study: 24417761

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg · kg(‐1) loading dose over 10 min followed by 0.5 μg · kg(‐1) · h(‐1) infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C) with no dexmedetomidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (D and C)
Number of subjects: 60
Study: 22650767

Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Chart based algorithmic support system
Number of subjects: 1600
Study: 20482477

Group type: EXPERIMENTAL
Intervention: Walk training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cycle training
Number of subjects: 36
Study: 18773781

Group type: EXPERIMENTAL
Intervention: Initial training group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed training group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 24
Study: 17060387

Group type: EXPERIMENTAL
Intervention: MV+SB (stenting both the main vessel and the side branch)
Number of subjects: 413

Group type: COMPARATOR
Intervention: MV (stenting the main vessel only, with optional stenting of the side branch)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: MV+SB
Number of subjects: 413

Group type: COMPARATOR
Intervention: MV
Number of subjects: 413
Study: 12525719

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 1086
Study: 10782589

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (ID) 0.15 mL
Number of subjects: 763

Group type: COMPARATOR
Intervention: Intramuscular vaccination (IM) 1.0 mL
Number of subjects: 763
Study: 8730607

Group type: EXPERIMENTAL
Intervention: Reduced-fat products
Number of subjects: 80

Group type: COMPARATOR
Intervention: Full-fat products
Number of subjects: 80
Study: 1881719

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 34

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 34
Study: 6813899

Group type: EXPERIMENTAL
Intervention: Butoctamide hydrogen succinate (BAHS) 600 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (linoleic acid)
Number of subjects: 6
Study: 29882110

Group type: EXPERIMENTAL
Intervention: Mental/incisive nerve block (MINB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 64
Study: 29071984

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham‐Electroacupuncture (sham‐EA)
Number of subjects: 88
Study: 25979975

Group type: EXPERIMENTAL
Intervention: Highest quartile of pulse pressure (PP)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Highest quartile of systolic blood pressure (SBP)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Highest quartile of diastolic blood pressure (DBP)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Number of subjects: 1099
Study: 23417317

Group type: EXPERIMENTAL
Intervention: Argireline applied twice daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Argireline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21484775

Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1252
Study: 19586727

Group type: EXPERIMENTAL
Intervention: Standard care plus contingency management (CM)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 393
Study: 18200995

Group type: EXPERIMENTAL
Intervention: Arndt bronchial blocker (ABB) for right-sided surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-lumen endotracheal tube (DLT) for right-sided surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Arndt bronchial blocker (ABB) for left-sided surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-lumen endotracheal tube (DLT) for left-sided surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both devices (ABB and DLT)
Number of subjects: 40
Study: 14990522

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy by general practitioners (5 to 7 sessions of 30 minutes each)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 151